{"id":"placebo-matched-to-sc0062","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"As a placebo matched to SC0062, this product is designed to be indistinguishable from the active investigational drug SC0062 in appearance, taste, and administration route, allowing for blinded comparison in clinical trials. It contains no active ingredient and serves as a control to isolate the therapeutic effect of SC0062 from placebo response.","oneSentence":"This is a placebo control formulation matched to SC0062, containing no active pharmaceutical ingredient.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:27:57.200Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06819826","phase":"PHASE3","title":"A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria","status":"RECRUITING","sponsor":"Biocity Biopharmaceutics Co., Ltd.","startDate":"2025-02-14","conditions":"IgA Nephropathy (IgAN)","enrollment":360}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo matched to SC0062","genericName":"Placebo matched to SC0062","companyName":"Biocity Biopharmaceutics Co., Ltd.","companyId":"biocity-biopharmaceutics-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}